Rencofilstat
Phase 2Small molecule
Rencofilstat is one of 32 small molecule programs targeting Fibrosis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
35 competitors in Fibrosis
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Actemra
RocheApproved
Cellcept
RocheApproved
Vemlidy
GileadApproved
Lexiscan
AstellasApproved
Esbriet
LLegacy Health System
Approved
Rayos
RRoxane Laboratories
Approved
Glucophage
EMD SeronoApproved
Rapamune
PPrism Pharmaceuticals
Approved
Viagra
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rencofilstat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHepion Pharmaceuticals, Inc.